Subsidiary of Medplus faces drug license suspension in Karnataka; potential revenue loss cited
Medplus Health Services Limited has received an update regarding the regulatory status of a subsidiary, Optival Health Solutions Private Limited, which faces multiple license suspensions for stores located in Karnataka. The company was informed that the subsidiary's Drug Licenses have been suspended following orders from the local Drugs Control Administration.The suspension pertains to stores situated at gajendragad and collegr road in Gadag, Karnataka. These actions were initiated under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.
Details concerning the licensing issue and its consequences have been documented as follows:
| Authority | Action Taken | Date of Order Receipt | Violation(s) | Financial Impact |
|---|---|---|---|---|
| Assistant Director, Drugs Control Administration, Circle Gadag Karnataka | Suspension of Drug License for one day of each store situated at gajendragad and collegr road Gadag Karnataka. | 29.06.2026 | Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 | Potential Revenue Loss of Rs 0.32 lacs and Rs.0.47 lacs respectively. |
The information provided in the report details the regulatory actions against Optival Health Solutions Private Limited and specifies the potential financial impact linked to the suspension of the Drug Licenses at both locations.
MEDPLUS Stock Price Movement
Medplus Health Services Limited gained 0.89% today in post-market trading, closing the session at ₹810.75. The stock saw a traded volume of 269,804 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.